Skip header and navigation

1 records – page 1 of 1.

Allergic bronchopulmonary aspergillosis in cystic fibrosis. A European epidemiological study. Epidemiologic Registry of Cystic Fibrosis.

https://arctichealth.org/en/permalink/ahliterature32533
Source
Eur Respir J. 2000 Sep;16(3):464-71
Publication Type
Article
Date
Sep-2000
Author
G. Mastella
M. Rainisio
H K Harms
M E Hodson
C. Koch
J. Navarro
B. Strandvik
S G McKenzie
Author Affiliation
Dept of Pulmonary and Digestive Diseases of Developmental Age, Cystic Fibrosis Center, Verona, Italy.
Source
Eur Respir J. 2000 Sep;16(3):464-71
Date
Sep-2000
Language
English
Publication Type
Article
Keywords
Adolescent
Adult
Aspergillosis, Allergic Bronchopulmonary - complications - epidemiology - physiopathology
Child
Child, Preschool
Cystic Fibrosis - complications
Europe - epidemiology
Female
Forced expiratory volume
Humans
Infant
Male
Middle Aged
Prevalence
Research Support, Non-U.S. Gov't
Abstract
Allergic bronchopulmonary aspergillosis (ABPA) is a disease resulting from a hypersensitivity response to Aspergillus fumigatus, although the pathogenesis of the disease is unknown and its prevalence in cystic fibrosis (CF) is still poorly defined. Data from the Epidemiologic Registry of Cystic Fibrosis (ERCF) on 12,447 CF patients gathered from 224 CF centres in nine European countries were analysed. The ERCF definition of ABPA diagnosis is a positive skin test and serum precipitins to A. fumigatus, together with serum immunoglobulin (Ig)E levels >1,000 U x mL(-1) and additional clinical or laboratory parameters. The overall prevalence of ABPA in the ERCF population was 7.8% (range: 2.1% in Sweden to 13.6% in Belgium). Prevalence was low or =20-12.9% in those with FEV1
Notes
Comment In: Eur Respir J. 2001 May;17(5):1052-311488309
PubMed ID
11028661 View in PubMed
Less detail